Your browser doesn't support javascript.
loading
Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder.
Song, Ruize; Shi, Yachen; Li, Xianrui; Zhu, Jianli; Zhang, Hongxing; Li, Kun; Wang, Bi; Zhang, Haisan; Yang, Yongfeng; Gao, Lijuan; Zhao, Yang; Zhang, Zhijun.
Afiliación
  • Song R; Department of Neurology, School of Medicine, Affiliated ZhongDa Hospital, Southeast University, Nanjing, China.
  • Shi Y; Department of Neurology, School of Medicine, Affiliated ZhongDa Hospital, Southeast University, Nanjing, China.
  • Li X; Department of Psychology, Xinxiang Medical University, Xinxiang, China.
  • Zhu J; Department of Psychology, Xinxiang Medical University, Xinxiang, China.
  • Zhang H; Department of Psychology, Xinxiang Medical University, Xinxiang, China.
  • Li K; Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Wang B; Department of Psychology, Xinxiang Medical University, Xinxiang, China.
  • Zhang H; Department of Psychology, Xinxiang Medical University, Xinxiang, China.
  • Yang Y; Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Gao L; Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Zhao Y; Department of Neurology, School of Medicine, Affiliated ZhongDa Hospital, Southeast University, Nanjing, China.
  • Zhang Z; Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
Front Psychiatry ; 12: 678384, 2021.
Article en En | MEDLINE | ID: mdl-34777034
Background: The evaluation of treatment response to antidepressant therapy commonly depends on neuropsychologic assessments, as there are currently no suitable biomarkers. Previous research has identified a panel of increased proteins in patients with major depressive disorder (MDD), including antithrombin III (ATIII), as potential biomarkers of depression. Methods: A total of 90 MDD patients were recruited. Of these, 74 patients received occipital repetitive transcranial magnetic stimulation (rTMS) as individualized, standard, or sham treatment for 5 days, and underwent the complete procedure, including clinical assessments, blood collection, and protein measurement. Results: After treatment, ATIII was significantly decreased in both the individualized and standard groups (both p < 0.001) relative to the sham group. In the individualized group, reduction in ATIII was associated with improvements in several neuropsychological assessments. Furthermore, ATIII at baseline in the standard group and after individualized rTMS showed good performance for evaluating or predicting the response to five-day treatment (AUC = 0.771, 95% CI, 0.571-0.971; AUC = 0.875, 95% CI, 0.714-1.000, respectively) and remission at follow-up (AUC = 0.736, 95% CI, 0.529-0.943; AUC = 0.828, 95% CI, 0.656-1.000, respectively). Lastly, both baseline ATIII and change in ATIII showed good predictive value for the 24-item Hamilton Depression Rating Scale at follow-up (p = 0.024 and 0.023, respectively). Conclusion: Our study revealed a reduction in ATIII after occipital rTMS in MDD patients and a relationship between change in ATIII and therapeutic response. Taken together, these findings provide evidence for the potential of ATIII as a biomarker for the evaluation and prediction of antidepressive effects.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Psychiatry Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Psychiatry Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza